Table 2.
Status and variation of clinical programs (P-1: Program-1, P-2: Program-2) based on usage by patient phenotypes (Information extracted from heatmap shown in Fig. S1).
| Program | State on day 1 (baseline) | State on day 20 (untreated) | Variation in program during untreated disease course | State after anti-IL6 initiation on optimal day | State after anti-IL6R initiation on optimal day | State after dexamethasone initiation on optimal day |
|---|---|---|---|---|---|---|
| Older | ||||||
| Older P-1 | Low | Low | High | Moderately high | Moderately high | Moderately high |
| Older P-2 | Low | High | Moderate | Low | Low | Low |
| Hyperinflamed | ||||||
| Hyperinflamed P-1 | Low | Low | High | Low | Low | Low |
| Hyperinflamed P-2 | Low | High | Moderate | Low | Moderately high | Low |
| Hypertensive | ||||||
| Hypertensive P-1 | Low | Low | Low | Moderately high | Moderately high | Moderately high |
| Hypertensive P-2 | Low | Moderately high | High | Low | Low | Low |
| Diabetics | ||||||
| Diabetic P-1 | Low | Moderately high | Low | Moderately high | Moderately high | Moderately high |
| Diabetic P-2 | Low | Low | High | Low | Low | Low |
| Obese | ||||||
| Obese P-1 | Low | Moderately high | Low | Moderately high | Moderately high | Moderately high |
| Obese P-2 | Low | Low | High | Low | Low | Low |
| Healthy | ||||||
| Healthy P-1 | Low | Low | Low | Low | Low | Low |
| Healthy P-2 | Low | Low | High | Low | Low | Low |